Ying Yuan

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 48

Top Topics

Locally Advanced

Prognostic Factors

Top Venues

Cancer communications (London, England)

Technology in cancer research & treatment

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Ning Zhu, Yan Zhang, Mi Mi, Yuwei Ding, Shanshan Weng, Jia Zheng, Yang Tian, Ying Yuan
The death burden of colorectal cancer attributable to modifiable risk factors, trend analysis from 1990 to 2019 and future predictions. Cancer medicine 13 (7) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) (2024)
Liubo Chen, Tian Jin, Yimin Fang, Gaoqi Wu, Ying Yuan
Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study. Journal of gastroenterology and hepatology 39 (6) (2024)
Liubo Chen, Tian Jin, Yimin Fang, Gaoqi Wu, Ying Yuan
Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study. Journal of gastroenterology and hepatology 39 (6) (2024)
Liubo Chen, Tian Jin, Yimin Fang, Gaoqi Wu, Ying Yuan
Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study. Journal of gastroenterology and hepatology (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Ning Zhu, Yan Zhang, Mi Mi, Yuwei Ding, Shanshan Weng, Jia Zheng, Yang Tian, Ying Yuan
The death burden of colorectal cancer attributable to modifiable risk factors, trend analysis from 1990 to 2019 and future predictions. Cancer medicine 13 (7) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Jinjie He, Yue Liu, Chengcheng Liu, Hanguang Hu, Lifeng Sun, Dong Xu, Jun Li, Junye Wang, Xiaobing Chen, Rongbo Lin, Yi Jiang, Yanqiao Zhang, Weisheng Zhang, Ying Cheng, Xiaohong Wu, Mingzhi Fang, Enxiao Li, Ye Xu, Ye Chen, Jiayi Li, Yanyan Cui, Zhanyu Pan, Songnan Zhang, Ying Yuan, Kefeng Ding
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technology in cancer research & treatment 22 (2023)
Xinyu Li, Jiaqi Chen, Adilai Aisa, Yuwei Ding, Ding Zhang, Ying Yuan
Targeting BRCA-Mutant Biliary Tract Cancer: Current Evidences and Future Perspectives. Journal of digestive diseases (2023)
Jinjie He, Yue Liu, Chengcheng Liu, Hanguang Hu, Lifeng Sun, Dong Xu, Jun Li, Junye Wang, Xiaobing Chen, Rongbo Lin, Yi Jiang, Yanqiao Zhang, Weisheng Zhang, Ying Cheng, Xiaohong Wu, Mingzhi Fang, Enxiao Li, Ye Xu, Ye Chen, Jiayi Li, Yanyan Cui, Zhanyu Pan, Songnan Zhang, Ying Yuan, Kefeng Ding
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technology in cancer research & treatment 22 (2023)
Yulin Chen, Ruixi Wan, Zhongyu Zou, Lihui Lao, Guojian Shao, Yingying Zheng, Ling Tang, Ying Yuan, Yun Ge, Chuan He, Shixian Lin
O-GlcNAcylation determines the translational regulation and phase separation of YTHDF proteins. Nature cell biology 25 (11) (2023)
Jinjie He, Yue Liu, Chengcheng Liu, Hanguang Hu, Lifeng Sun, Dong Xu, Jun Li, Junye Wang, Xiaobing Chen, Rongbo Lin, Yi Jiang, Yanqiao Zhang, Weisheng Zhang, Ying Cheng, Xiaohong Wu, Mingzhi Fang, Enxiao Li, Ye Xu, Ye Chen, Jiayi Li, Yanyan Cui, Zhanyu Pan, Songnan Zhang, Ying Yuan, Kefeng Ding
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technology in cancer research & treatment 22 (2023)
Jinjie He, Yue Liu, Chengcheng Liu, Hanguang Hu, Lifeng Sun, Dong Xu, Jun Li, Junye Wang, Xiaobing Chen, Rongbo Lin, Yi Jiang, Yanqiao Zhang, Weisheng Zhang, Ying Cheng, Xiaohong Wu, Mingzhi Fang, Enxiao Li, Ye Xu, Ye Chen, Jiayi Li, Yanyan Cui, Zhanyu Pan, Songnan Zhang, Ying Yuan, Kefeng Ding
A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol. Technology in cancer research & treatment 22 (2023)
Wenlong Ding, Chao Liu, Yulin Chen, Jiayu Gu, Chengzhu Fang, Linzhen Hu, Jisheng Liu, Ying Yuan, Xin-Hua Feng, Shixian Lin
Computational design and genetic incorporation of lipidation mimics in living cells. Nature chemical biology (2023)
Shu-Kui Qin, Jin Li, Yuxian Bai, Zishu Wang, Zhendong Chen, Rui-Hua Xu, Jian-Ming Xu, Hong-Mei Zhang, Jia Chen, Ying Yuan, Tianshu Liu, Lin Yang, Haijun Zhong, Donghui Chen, Lin Shen, Chunyi Hao, Deliang Fu, Ying Cheng, Jianwei Yang, Qiong Wang, Baoli Qin, Hongming Pan, Jun Zhang, Xianhong Bai, Qingshan Zheng
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Yier Lu, Chenyang Ye, Ying Yuan
Phenotypic characteristics and T cell receptor properties in melanoma: deciphering the correlation at single-cell resolution. Signal transduction and targeted therapy 7 (1) (2022)
Xianhua Fu, Jieer Ying, Liu Yang, Wei-Jia Fang, Weidong Han, Hanguang Hu, Suzhan Zhang, Ying Yuan
Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: A phase 2 trial. Cancer science (2022)
Ning Zhu, Hanguang Hu, Ying Yuan
Circulating tumor DNA analysis: potential to revise adjuvant therapy for stage II colorectal cancer. Signal transduction and targeted therapy 7 (1) (2022)
Feng-Hua Wang, Ming-Ming He, Jian Xiao, Yan-Qiao Zhang, Xiang-Lin Yuan, Wei-Jia Fang, Yan Zhang, Wei Wang, Xiao-Hua Hu, Zhi-Gang Ma, Yi-Chen Yao, Zhi-Xiang Zhuang, Yingying Shi, Jie-Er Ying, Ying Yuan, Qing-Feng Zou, Zeng Qing Guo, Xiang-Yuan Wu, Ying Jin, Zong-Jiong Mai, Zhi-Qiang Wang, Hong Qiu, Ying Guo, Si-Mei Shi, Shuang-Zhen Chen, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (19) (2022)
Xian Zhong, Xiaoye Hu, Peng Zhao, Yuebing Wang, Xue Feng Fang, Jiayi Shen, Hong Shen, Ying Yuan
The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor. Cancer medicine 11 (10) (2022)
Yanjun Zhang, Yuan Fang, Yin Tang, Shixun Han, Junqi Jia, Xinyi Wan, Jiaqi Chen, Ying Yuan, Bin Zhao, Dong Fang
SMYD5 catalyzes histone H3 lysine 36 trimethylation at promoters. Nature communications 13 (1) (2022)
Xiaoqing Cheng, Fenglan Zhang, Jingwen Gong, Yige Li, Dan Zhou, Jing Wang, Eu Gene Vong, Ying Yuan, Maode Lai, Dandan Zhang
Identification of potential functional variants and genes at 18q21.1 associated with the carcinogenesis of colorectal cancer. PLoS genetics 18 (2) (2022)
Mi Mi, Chenyang Ye, Ying Yuan
Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair-deficient, locally advanced rectal cancer. Signal transduction and targeted therapy 7 (1) (2022)
Hang Yang, Xinyi Zhou, Dongliang Fu, Chenqin Le, Jiafeng Wang, Quan Zhou, Xiangrui Liu, Ying Yuan, Ke-Feng Ding, Qian Xiao
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer communications (London, England) (2022)
Mengyuan Yang, Yingxin Zhao, Yuwei Ding, Juan Wang, Yinuo Tan, Dong Xu, Ying Yuan
Erratum to A truncated protein product of the germline variant of the DUOX2 gene leads to adenomatous polyposis. Cancer biology & medicine (2022)
Yuan Fang, Yin Tang, Yanjun Zhang, Yixin Pan, Junqi Jia, Zhongxing Sun, Weiwu Zeng, Jiaqi Chen, Ying Yuan, Dong Fang
The H3K36me2 methyltransferase NSD1 modulates H3K27ac at active enhancers to safeguard gene expression. Nucleic acids research 49 (11) (2021)
Hongxia Zhao, Wenlong Ding, Jia Zang, Yang Yang, Chao Liu, Linzhen Hu, Yulin Chen, Guanglong Liu, Yu Fang, Ying Yuan, Shixian Lin
Directed-evolution of translation system for efficient unnatural amino acids incorporation and generalizable synthetic auxotroph construction. Nature communications 12 (1) (2021)
Lina Qi, Jiani Chen, Biting Zhou, Kailun Xu, Kailai Wang, Zhihao Fang, Yingkuan Shao, Ying Yuan, Shu Zheng, Wangxiong Hu
HomeoboxC6 promotes metastasis by orchestrating the DKK1/Wnt/β-catenin axis in right-sided colon cancer. Cell death & disease 12 (4) (2021)
Ying-Xin Zhao, Xiao-Ye Hu, Xian Zhong, Hong Shen, Ying Yuan
High-intensity focused ultrasound treatment as an alternative regimen for myxofibrosarcoma. Dermatologic therapy 34 (2) (2021)
Mengyuan Yang, Xian Zhong, Ying Yuan
Does Baking Soda Function as a Magic Bullet for Patients With Cancer? A Mini Review. Integrative cancer therapies 19 (2021)
Yi Cheng, Shanshan Weng, Linzhen Yu, Ning Zhu, Mengyuan Yang, Ying Yuan
The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors. Integrative cancer therapies 18 (2020)
Ruihua Xu, Shukui Qin, Weijian Guo, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Hongming Pan, Yongqian Shu, Ying Yuan, Jianfeng Zhou, Nong Xu, Tianshu Liu, Dong Ma, Changping Wu, Ying Cheng, Jianming Xu, Donghui Chen, Wei Li, Sanyuan Sun, Zhuang Yu, Peiguo Cao, Jian Li, Haihui Chen, Jiejun Wang, Shubin Wang, Hongbing Wang, Ning Wang, Bin Zhang, Rubing Han, Weiguo Su, Xiaojun Guo, Jin Li
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial. Future oncology (London, England) 17 (11) (2020)
Yi Cheng, Xue-Feng Fang, Han-Guang Hu, Jiang Wang, Li-Feng Sun, Ying Yuan
Successful treatment of metastatic colorectal cancer with synchronous BRAF V600E mutation and dMMR with BGB-A317. Immunotherapy 12 (4) (2020)
Wei Lu, Dongliang Fu, Xiangxing Kong, Zhiheng Huang, Maxwell Hwang, Yingshuang Zhu, Liubo Chen, Kai Jiang, Xinlin Li, Yihua Wu, Jun Li, Ying Yuan, Ke-Feng Ding
FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms. Cancer medicine 9 (4) (2020)
Ning Zhu, Shanshan Weng, Juan Wang, Jiaqi Chen, Linzhen Yu, Xuefeng Fang, Ying Yuan
Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. Journal of cancer research and clinical oncology 145 (12) (2019)
Chenhan Zhong, Jiekai Yu, Dan Li, Kai Jiang, Yang Tang, Mengyuan Yang, Hong Shen, Xuefeng Fang, Ke-Feng Ding, Shu Zheng, Ying Yuan
Zyxin as a potential cancer prognostic marker promotes the proliferation and metastasis of colorectal cancer cells. Journal of cellular physiology (2019)
Xiu Jun Tang, Xue Feng Fang, Li Zhen Zhu, Qi Chun Wei, Xue Li Bai, Ting Bo Liang, Ying Yuan
Metastatic mixed acinar-neuroendocrine carcinoma of the pancreas treated by a multidisciplinary team: A case report and brief review of the literature. Journal of digestive diseases 20 (6) (2019)
Mengyuan Yang, Lizhen Zhu, Dong Xu, Shanshan Weng, Xuefeng Fang, Caixia Dong, Hanguang Hu, Ying Yuan
How should we correctly interpret biallelic germline truncating variant of MLH3 in hereditary colorectal cancer? Genetics in medicine : official journal of the American College of Medical Genetics 21 (11) (2019)
Dan Li, Chenhan Zhong, Xiujun Tang, Linzhen Yu, Kefeng Ding, Ying Yuan
Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy. Journal of cancer research and clinical oncology 144 (5) (2018)
Mengjie Jiang, Yinuo Tan, Xiaofen Li, Jianfei Fu, Hanguang Hu, Xianyun Ye, Ying Cao, Jinghong Xu, Ying Yuan
Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms. Gastroenterology research and practice 2017 (2017)